Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis [0.03%]
免疫检查点抑制剂治疗实体器官移植受者晚期癌症的疗效和安全性：系统评价和个体患者数据meta分析
Nida Saleem,Jiayue Wang,Angela Rejuso et al.
Nida Saleem et al.
Importance: Immune checkpoint inhibitors (ICIs) have improved overall survival in patients with advanced-stage cancers. However, data on their efficacy and safety in solid organ transplant recipients (SOTRs) are limited. ...
Nina B Curkovic,Douglas B Johnson,Eva Rawlings Parker
Nina B Curkovic
Both paraneoplastic dermatomyositis in patients with metastatic melanoma and dermatomyositis presenting as an immune-related adverse event in patients receiving immune checkpoint inhibitors (ICI) are rare.
Online risk scores for pre- and postoperative prediction of early recurrence in hepatocellular carcinoma patients undergoing conversion liver resection after tyrosine kinase inhibitors and immune checkpoint inhibitors therapy [0.03%]
Kong-Ying Lin,Hong-Zhi Liu,Jian-Wei Liu et al.
Kong-Ying Lin et al.
Background: Conversion therapy with tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) offers the potential for curative resection in unresectable hepatocellular carcinoma (HCC).
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC [0.03%]
一线免疫检查点抑制剂单药或联合化疗治疗KRAS不同突变状态的晚期NSCLC患者的疗效和安全性：基于真实世界证据的研究
David J Cantor,Halla Nimeiri,Leora Horn et al.
David J Cantor et al.
Introduction: Prior studies evaluating the efficacy of first line (1 L) immune checkpoint inhibitor (ICI) monotherapy or combined chemoimmunotherapy in advanced NSCLC found improved outcomes with chemoimmunotherapy indepe...
Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Network Meta-Analysis [0.03%]
免疫检查点抑制剂治疗晚期或转移性食管鳞癌疗效和安全性的网络 meta 分析
Ahmed Ibrahim,Laila Shalabi,Ahmed Farid Gadelmawla et al.
Ahmed Ibrahim et al.
Background: Combining immune checkpoint inhibitors (ICIs) with chemotherapy has significantly transformed cancer treatment, offering better options for esophageal squamous cell carcinoma (ESCC).
Biological modifications of the immune response to COVID-19 vaccine in patients treated with rituximab and immune checkpoint inhibitors [0.03%]
利妥昔单抗和免疫检查点抑制剂治疗患者对COVID-19疫苗的免疫反应生物标志物修改
Francesco Ravera,Martina Dameri,Isabella Lombardo et al.
Francesco Ravera et al.
In this work, we investigate the immune response to the third dose of COVID-19 mRNA vaccine in cancer-free individuals, patients with non-Hodgkin lymphoma treated with rituximab (RTX), and patients with solid tumors receiving immune checkpoint inhibitors (ICIs).
Re-appraisal of Standard of Care Imaging to Identify Predictors of Treatment Outcomes among Patients with Bladder and Upper Tract Urothelial Cancers [0.03%]
重新评估标准影像护理以识别膀胱和上尿路尿路上皮癌患者治疗结果的预测因素
Shelby Harper,Erick M Remer,Nima Almassi
Shelby Harper
Multimodal treatment is often employed, with transurethral resection and intravesical therapy standard of care for non-muscle-invasive disease; neoadjuvant systemic therapy followed by radical cystectomy or trimodal therapy for muscle-invasive disease; and combination immune checkpoint inhibitors and
Recent Advances in Cancer Immunotherapy Aided by Regulatory Non-Coding RNA: A Review [0.03%]
癌症免疫治疗的最新进展：由调控非编码RNA助推——综述文章
Debabrat Baishya,Arpita Barman,Bijuli Rabha et al.
Debabrat Baishya et al.
These ncRNAs influence the tumor microenvironment (TME), modulate the immune system, and affect the efficacy of immune checkpoint inhibitors and T cell therapies by regulating various signaling pathways.This review article explores the diagnostic and therapeutic potential of ncRNAs in cancer immunotherapy
Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP [0.03%]
经导管动脉化疗栓塞-阿霉素结肠癌明胶海绵微球-免疫检查点抑制剂与经导管动脉化疗栓塞-结肠癌明胶海绵微球-免疫检查点抑制剂治疗肝细胞癌疗效及安全性的比较：基于血清甲胎蛋白动态变化的预后分析
Wenli Li,Mingjian Lu,Guosheng Yuan et al.
Wenli Li et al.
Background: To evaluate the efficacy and safety of 2 combination treatments for hepatocellular carcinoma (HCC): 1) transarterial chemoembolization (TACE) with hepatic arterial infusion chemotherapy (HAIC) combined with molecular targeted therapies (MTTs) and immune checkpoint inhibitors
Role of immunotherapy in early breast cancer: past, present, and future [0.03%]
免疫疗法在早期乳腺癌治疗中的作用：过去、现在和未来展望
Karissa Britten,Aditya Bardia,Nicholas McAndrew
Karissa Britten
The development of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment over the last decade, starting with the US Food and Drug Administration (FDA) approval of ipilimumab in 2011.
耗时 0.14376 秒，为您在
48252782
条记录里面共找到 10000 篇文章 [XML]